Cyclophosphamide

SKU: orb1710689

Description

Cyclophosphamide is a DNA-alkylating agent that inhibits cancer cell proliferation by disrupting DNA replication and transcription. It is widely used in oncology research for studying chemotherapy mechanisms and efficacy in both in vitro cell cultures and in vivo animal models.

Research Area

Immunology & Inflammation, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 50-18-0
• MW: 261.09
• Purity: 98.26% (May vary between batches)
• Formula: C₇H₁₅Cl₂N₂O₂P
• SMILES: ClCCN(CCCl)P1(=O)NCCCO1
• Target: DNA Alkylator/Crosslinker|||MRP|||DNA
• Solubility: H2O:20 mg/mL (76.6 mM);Saline:20 mg/mL (76.6 mM);DMSO:255 mg/mL (976.67 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (19.15 mM)

Bioactivity

• Target IC50:
  NCI-H522 cells:67.9 μM|HL-60 cells:8.79 μM|L1210 cells:> 300 μM|MCF-7 cells:0.16 μM|T47D cells:69 μM|DU-145 cells:52.5 μM|COS-1 cells:125.43 μM|HCT15 cells:74.32 μM|HepG2 cells:0.24 μM|HeLa cells:71.4 μM|MDA-MB-231 cells:0.09 μM|HEp-2 cells:> 100 μM|PA-1 cells:64.12 μM|K562 cells:0.153 μM
  Read more...
• In Vivo:
  METHODS: Cyclophosphamide induces ovarian insufficiency (POI) by activating primordial follicles. Cyclophosphamide (150 mg/kg; Intraperitoneal injection A single dose was injected into 5-week-old female Balb/C mice. RESULTS: The number of primary follicles in the ovaries decreases. METHODS: Cyclophosphamide induces bone marrow suppression by interfering with the proliferation and differentiation of bone marrow (BM) cells. Cyclophosphamide (150 mg/kg; Intraperitoneal injection A single dose was injected into 56-week-old male Swiss mice. RESULTS: It causes significant changes in the structure of bone marrow tissue, reduces the bone marrow/red blood cell ratio, and decreases the number of white blood cells in the blood.
  Read more...
• In Vitro:
  METHODS: Human HL60 cells were treated with Cyclophosphamide, and cytotoxicity was detected by the MTT method. RESULTS: Cyclophosphamide inhibited the growth of HL60 cells, with an IC50 of 8.79 μM. METHODS: Human K562 cells were treated with Cyclophosphamide for 48 hours, and the cell growth inhibition was detected by the MTT method. RESULTS: Cyclophosphamide inhibited the growth of K562 cells, with an IC50 of 0.153 μM. METHODS: Human MCF7 cells were treated with Cyclophosphamide for 48 hours, and cytotoxicity was detected using the SRB method. RESULTS: Cyclophosphamide inhibited the growth of K562 cells, with an IC50 of 10 mM. METHODS: COS-1 cells and HCT-15 cells were treated with Cyclophosphamide for 24 hours, and cytotoxicity was detected by the MTT method. RESULTS: Cyclophosphamide inhibited the growth of COS-1 cells (IC50=125.43 μM) and HCT-15 cells (IC50=74.32 μM). METHODS: DU-145 cells were treated with Cyclophosphamide, and cytotoxicity was detected by the MTT method. RESULTS: Cyclophosphamide inhibited DU-145 cells (IC50=52.5 μM). METHODS: HCT-15 cells and HEK-293T cells were treated with Cyclophosphamide for 24 hours, and the cell growth inhibition was detected by the MTT method. RESULTS: Cyclophosphamide inhibited the growth of COS-1 cells (IC50=76.32 μM) and did not inhibit the growth of HEK-293T cells (IC5> 100 μM).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DNAAlkylator, DNA, DNA Alkylator, DNA Alkylator/Crosslinker, Crosslinker, Cyclophosphamide, Inhibitor, inhibit, MRP1

Compound Identifiers

PubChem CID

2907